{
    "data": [
        {
            "id": "4476147",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-21T00:30:17-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1274844114/image_1274844114.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Waiting For The Pipeline Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "353641",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4476147-vertex-waiting-for-the-pipeline-success"
            }
        },
        {
            "id": "4473826",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-07T09:58:04-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1290302520/image_1290302520.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Recent Pipeline Updates Show Vertex Is Not Just About Cystic Fibrosis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "352127",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4473826-recent-pipeline-updates-show-vertex-is-not-just-about-cystic-fibrosis"
            }
        },
        {
            "id": "4470077",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-16T17:01:01-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442152/image_1284442152.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Stock: Slowing Growth, But It's Attractively Valued Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "349505",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4470077-vertex-stock-slowing-growth-but-its-attractively-valued-now"
            }
        },
        {
            "id": "4468855",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-12T08:31:06-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257149042/image_1257149042.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex's Q3 Report As Good As One Could Expect",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348916",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4468855-vertexs-q3-report-as-good-as-one-could-expect"
            }
        },
        {
            "id": "4457616",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-29T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224202684/image_1224202684.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Reasons To Buy Vertex Below $200",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343196",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4457616-vertex-stock-reasons-to-buy-below-200"
            }
        },
        {
            "id": "4451461",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-24T08:10:13-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1268430935/image_1268430935.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: Cystic Fibrosis Leader With Lean Operating Model",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104695",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338246",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4451461-vertex-pharmaceuticals-cystic-fibrosis-leader"
            }
        },
        {
            "id": "4451268",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-23T11:00:22-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1256323645/image_1256323645.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: Why I'm Buying This Undervalued Monopoly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106272",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338534",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4451268-vertex-pharmaceuticals-why-im-buying-this-undervalued-monopoly"
            }
        },
        {
            "id": "4438597",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-10T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227231206/image_1227231206.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharma: Underestimated",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105503",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "332578",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4438597-vertex-pharma-underestimated"
            }
        },
        {
            "id": "4435324",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-17T10:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/936497024/image_936497024.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Moving Past The Disappointing VX-864 Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "329762",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4435324-vertex-moving-past-disappointing-vx-864-results"
            }
        },
        {
            "id": "4433261",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-05T09:31:51-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Spotlight On REITs, Apple, Chewy And GameStop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4433261-stocks-to-watch-spotlight-on-reits-apple-chewy-and-gamestop"
            }
        },
        {
            "id": "4432574",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-02T08:58:57-04:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172456549/image_172456549.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: An Undervalued Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105578",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "327728",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4432574-vertex-pharmaceuticals-stock-vrtx-undervalued-pipeline"
            }
        },
        {
            "id": "4432103",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-30T07:27:02-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/855467422/image_855467422.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Exceptional CF Franchise And Undervalued Pipeline Send Strong Buy Signals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "327318",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4432103-vertex-exceptional-cf-franchise-and-undervalued-pipeline-send-strong-buy-signals"
            }
        },
        {
            "id": "4428091",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-12T21:52:32-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1131583289/image_1131583289.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: While The Market Remains Indifferent, Now Is The Time To Commit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106043",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "325046",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4428091-vertex-stock-vrtx-market-remains-indifferent-now-is-time-to-commit"
            }
        },
        {
            "id": "4416560",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-29T08:04:46-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: An Undervalued Business With A Promising Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "318984",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4416560-vertex-stock-undervalued-business-promising-pipeline"
            }
        },
        {
            "id": "4415314",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-22T05:06:07-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209427002/image_1209427002.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Good Company, Fairly Valued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106075",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "318027",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4415314-vertex-good-company-fairly-valued"
            }
        },
        {
            "id": "4414225",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-16T09:45:00-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: 45% Upside Remains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105756",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "317399",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4414225-vertex-upside-remains"
            }
        },
        {
            "id": "4411970",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-06T09:08:50-05:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Spotlight On DraftKings, 5G Carriers And Roblox",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4411970-stocks-to-watch-spotlight-on-draftkings-5g-carriers-and-roblox"
            }
        },
        {
            "id": "4402927",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-02T23:20:17-05:00",
                "isLockedPro": false,
                "commentCount": 80,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Poised For Long-Term Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "311671",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4402927-vertex-pharmaceuticals-poised-for-long-term-growth"
            }
        },
        {
            "id": "4400625",
            "type": "article",
            "attributes": {
                "publishOn": "2021-01-24T12:40:00-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: A Play On Market Overreaction",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105962",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "310111",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4400625-vertex-pharmaceuticals-play-on-market-overreaction"
            }
        }
    ]
}